Figure 5. Microfluidic assessment of neutrophil adhesion profile can guide therapeutic decisions in sickle cell disease.

Subjects with SCD who have a moderate clinical phenotype where a smaller proportion of neutrophils are fully activated, present with relatively greater neutrophil binding to E-selectin and are more likely to benefit from therapies against E-selectin. In contrast, SCD individuals who exhibit a more severe clinical phenotype and presumably more neutrophils activated, present with lower neutrophil binding to E-selectin, likely mediated by enhanced L-selectin shedding, and may be unresponsive to therapies against E-selectin.